|
[1]
|
Matziorinis, A.M. and Koelsch, S. (2022) The Promise of Music Therapy for Alzheimer’s Disease: A Review. Annals of the New York Academy of Sciences, 1516, 11-17. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Tansey, M.G., et al. (2022) Inflammation and Immune Dysfunction in Parkinson Disease. Nature Reviews Immunology, 22, 657-673. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Kwon, H.S. and Koh, S.H. (2020) Neuroinflammation in Neu-rodegenerative Disorders: The Roles of Microglia and Astrocytes. Translational Neurodegeneration, 9, Article 42. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Forsyth, C.B., et al. (2011) Increased Intestinal Permeability Correlates with Sigmoid Mucosa α-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson’s Disease. PLOS ONE, 6, e28032. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wright Willis, A., et al. (2010) Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. Neuroepidemiology, 34, 143-151. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Tysnes, O.B. and Storstein, A. (2017) Epidemiology of Parkinson’s dis-ease. Journal of Neural Transmission, 124, 901-905. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Litvan, I., et al. (2003) Movement Disorders Society Scientific Issues Committee report: SIC Task Force Appraisal of Clinical Diag-nostic Criteria for Parkinsonian Disorders. Movement Disorders, 18, 467-486. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Raza, C., Anjum, R. and Shakeel, N.U.A. (2019) Parkinson’s Disease: Mechanisms, Translational Models and Management Strategies. Life Sciences, 226, 77-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Katzenschlager, R. (2014) Parkinson’s Disease: Recent Advances. Journal of Neurology, 261, 1031-1036. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Kim, S., et al. (2019) Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron, 103, 627-641.E7. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Julio-Pieper, M., Bravo, J.A., Aliaga, E. and Gotteland, M. (2014) Review Article: Intestinal Barrier Dysfunction and Central Nervous System Disorders—A Controversial Associ-ation. Alimentary Pharmacology & Therapeutics, 40, 1187-1201. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Lewis, C.V. and Taylor, W.R. (2020) Intestinal Barrier Dysfunction as a Therapeutic Target for Cardiovascular Disease. Ameri-can Journal of Physiology-Heart and Circulatory Physiology, 319, H1227-H1233. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Odenwald, M.A. and Turner, J.R. (2013) Intestinal Permeability Defects: Is It Time to Treat? Clinical Gastroenterology and Hepatology, 11, 1075-1083. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Yao, C., et al. (2022) Key Regulators of Intestinal Stem Cells: Diet, Microbiota, and Microbial Metabolites. Journal of Genetics and Genomics, 50, 735-746.
|
|
[15]
|
Díaz-Coránguez, M., Liu, X. and Antonetti, D.A. (2019) Tight Junctions in Cell Proliferation. International Journal of Molecular Sciences, 20, Ar-ticle 5972. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Camilleri, M., Lasch, K. and Zhou, W. (2012) Irritable Bow-el Syndrome: Methods, Mechanisms, and Pathophysiology. The Confluence of Increased Permeability, Inflammation, and Pain in Irritable Bowel Syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology, 303, G775-G785. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Suzuki, T. (2020) Regulation of the Intestinal Barrier by Nutrients: The Role of Tight Junctions. Animal Science Journal, 91, e13357. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Casini, A., et al. (2021) Distribution of α-Synuclein in Normal Human Je-junum and Its Relations with the Chemosensory and Neuroendocrine System. European Journal of Histochemistry, 65, No. 4. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Fasano, A., et al. (2015) Gastrointestinal Dysfunction in Parkinson’s Disease. The Lancet Neurology, 14, 625-639. [Google Scholar] [CrossRef]
|
|
[20]
|
Gehart, H. and Clevers, H. (2019) Tales from the Crypt: New Insights into Intestinal Stem Cells. Nature Reviews Gastroenterology & Hepatology, 16, 19-34. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Uematsu, S. and Fujimoto, K. (2010) The Innate Immune System in the Intestine. Microbiology and Immunology, 54, 645-657. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Liddle, R.A. (2018) Parkinson’s Disease from the Gut. Brain Research, 1693, 201-206. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Chandra, R., et al. (2017) α-Synuclein in Gut Endocrine Cells and Its Implications for Parkinson’s Disease. JCI Insight, 2, e92295. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Dogra, S.K., Doré, J. and Damak, S. (2020) Gut Microbiota Resili-ence: Definition, Link to Health and Strategies for Intervention. Frontiers in Microbiology, 11, Article 572921. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hou, K., et al. (2022) Microbiota in Health and Diseases. Signal Transduction and Targeted Therapy, 7, Article No. 135. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Voigt, R.M. and Bishehsari, F. (2021) The Intestinal Microbiota: Determinants of Resiliency? The Lancet Healthy Longevity, 2, e2-e3. [Google Scholar] [CrossRef]
|
|
[27]
|
Rutsch, A., Kantsjö, J.B. and Ronchi, F. (2020) The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Frontiers in Im-munology, 11, Article 604179. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Boertien, J.M., Pereira, P.A.B., Aho, V.T.E. and Scheperjans, F. (2019) Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review. Journal of Parkinson’s Disease, 9, S297-S312. [Google Scholar] [CrossRef]
|
|
[29]
|
Bercik, P., et al. (2009) Role of Gut-Brain Axis in Persistent Abnormal Feeding Behavior in Mice following Eradication of Helicobacter pylori Infection. American Journal of Physiolo-gy-Regulatory, Integrative and Comparative Physiology, 296, R587-R594. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Tan, A.H., Hor, J.W., Chong, C.W. and Lim, S.Y. (2021) Probi-otics for Parkinson’s Disease: Current Evidence and Future Directions. JGH Open, 5, 414-419. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Bao, Y., et al. (2023) Quantification of Non-Motor Symptoms in Parkin-sonian Cynomolgus Monkeys. Brain Sciences, 13, Article 1153. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Stocchi, F. and Torti, M. (2017) Constipation in Parkinson’s Dis-ease. International Review of Neurobiology, 134, 811-826. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Ueki, A. and Otsuka, M. (2004) Life Style Risks of Parkinson’s Disease: Association between Decreased Water Intake and Con-stipation. Journal of Neurology, 251, vii18-vii23. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
李剑兰, 余璇, 胡青婷, 等. 老年帕金森病与肠道菌群、短链脂肪酸和炎性因子相关性研究[J]. 实用老年医学, 2021, 35(3): 282-285.
|
|
[35]
|
Mirzaei, H., et al. (2022) Probiotics and the Treatment of Parkinson’s Disease: An Update. Cellular and Molecular Neurobiology, 42, 2449-2457. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Cryan, J.F., et al. (2019) The Microbiota-Gut-Brain Axis. Physiological Reviews, 99, 1877-2013. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Scheperjans, F., et al. (2015) Gut Microbiota Are Related to Par-kinson’s Disease and Clinical Phenotype. Movement Disorders, 30, 350-358. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Ning, J., et al. (2022) Investigating Casual Associations among Gut Mi-crobiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study. Journal of Alzheimer’s Disease, 87, 211-222. [Google Scholar] [CrossRef]
|
|
[39]
|
Aho, V.T.E., et al. (2019) Gut Microbiota in Parkinson’s Disease: Tem-poral Stability and Relations to Disease Progression. eBioMedicine, 44, 691-707. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Heintz-Buschart, A., et al. (2018) The Nasal and Gut Microbiome in Parkinson’s Disease and Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders, 33, 88-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
dos Santos, E.F., et al. (2009) Evidence That Folic Acid Deficiency Is a Major Determinant of Hyperhomocysteinemia in Parkinson’s Disease. Metabolic Brain Disease, 24, 257-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Heinzel, S., et al. (2021) Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. Annals of Neurology, 90, E1-E12. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Hill-Burns, E.M., et al. (2017) Parkinson’s Disease and Parkinson’s Dis-ease Medications Have Distinct Signatures of the Gut Microbiome. Movement Disorders, 32, 739-749. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Jaglin, M., et al. (2018) Indole, a Signaling Molecule Produced by the Gut Microbiota, Negatively Impacts Emotional Behaviors in Rats. Frontiers in Neuroscience, 12, Article 216. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
O’Farrell, K. and Harkin, A. (2017) Stress-Related Regulation of the Kynurenine Pathway: Relevance to Neuropsychiatric and Degenerative Disorders. Neuropharmacology, 112, 307-323. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Szabó, N., Kincses, Z.T., Toldi, J. and Vécsei, L. (2011) Altered Tryptophan Metabolism in Parkinson’s Disease: A Possible Novel Therapeutic Approach. Journal of the Neuro-logical Sciences, 310, 256-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Widner, B., Leblhuber, F. and Fuchs, D. (2002) Increased Neopterin Production and Tryptophan Degradation in Advanced Parkinson’s Disease. Journal of Neural Transmission, 109, 181-189. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Dalile, B., Van Oudenhove, L., Vervliet, B. and Verbeke, K. (2019) The Role of Short-Chain Fatty Acids In Microbiota-Gut-Brain Communication. Nature Reviews Gastroenterology & Hepatology, 16, 461-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Mirzaei, R., et al. (2021) Role of Microbiota-Derived Short-Chain Fatty Acids in Nervous System Disorders. Biomedicine & Pharmacotherapy, 139, Article ID: 111661. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Vijay, N. and Morris, M.E. (2014) Role of Monocarboxylate Transporters in Drug Delivery to the Brain. Current Pharmaceutical Design, 20, 1487-1498. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Hou, Y.F., et al. (2021) Gut Microbiota-Derived Propionate Mediates the Neuroprotective Effect of Osteocalcin in a Mouse Model of Parkinson’s Disease. Microbiome, 9, Article 34. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Chen, S.J., et al. (2022) Association of Fecal and Plasma Levels of Short-Chain Fatty Acids with Gut Microbiota and Clinical Severity in Patients with Parkinson Disease. Neurology, 98, e848-e858. [Google Scholar] [CrossRef]
|
|
[53]
|
Hirayama, M. and Ohno, K. (2021) Parkinson’s Disease and Gut Microbiota. Annals of Nutrition and Metabolism, 77, 28-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Dutta, G., Zhang, P. and Liu, B. (2008) The Lipopolysaccharide Parkinson’s Disease Animal Model: Mechanistic Studies and Drug Discovery. Fundamental & Clinical Pharmacology, 22, 453-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Mohr, A.E., et al. (2022) Lipopolysaccharide and the Gut Microbiota: Considering Structural Variation. FEBS Letters, 596, 849-875. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Góralczyk-Bińkowska, A., Szmajda-Krygier, D. and Kozłowska, E. (2022) The Microbiota-Gut-Brain Axis in Psychiatric Disorders. International Journal of Molecular Sciences, 23, Article 11245. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Brown, G.C. (2019) The Endotoxin Hypothesis of Neurodegeneration. Journal of Neuroinflammation, 16, Article 180. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Deng, I., et al. (2020) Lipopolysaccharide Animal Models of Par-kinson’s Disease: Recent Progress and Relevance to Clinical Disease. Brain, Behavior, & Immunity—Health, 4, Article ID: 100060. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Georgescu, D., Ancusa, O.E., Georgescu, L.A., Ionita, I. and Reisz, D. (2016) Nonmotor Gastrointestinal Disorders in Older Patients with Parkinson’s Disease: Is There Hope? Clin-ical Interventions in Aging, 11, 1601-1608. [Google Scholar] [CrossRef]
|
|
[60]
|
Gazerani, P. (20190 Probiotics for Parkinson’s Disease. International Journal of Molecular Sciences, 20, Article 4121.[CrossRef] [PubMed]
|
|
[61]
|
Corridoni, D., et al. (2012) Probiotic Bacteria Regulate Intestinal Epi-thelial Permeability in Experimental Ileitis by a TNF-Dependent Mechanism. PLOS ONE, 7, e42067. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Ait-Belgnaoui, A., et al. (2012) Prevention of Gut Leakiness by a Probiotic Treatment Leads to Attenuated HPA Response to an Acute Psychological Stress in Rats. Psychoneuroendo-crinology, 37, 1885-1895. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Cassani, E., et al. (2011) Use of Probiotics for the Treatment of Constipation in Parkinson’s Disease Patients. Minerva Gastroenterologica e Dietologica, 57, 117-121.
|
|
[64]
|
Tamtaji, O.R., et al. (2019) Clinical and Metabolic Response to Probiotic Administration in People with Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Nutrition, 38, 1031-1035. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Lu, C.S., et al. (2021) The Add-On Effect of Lactobacillus planta-rum PS128 in Patients with Parkinson’s Disease: A Pilot Study. Frontiers in Nutrition, 8, Article 650053. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Alfonsetti, M., Castelli, V. and d’Angelo, M. (222) Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson’s Disease. Nutrients, 14, Article 380. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Barichella, M., et al. (2016) Probiotics and Prebiotic Fiber for Constipa-tion Associated with Parkinson Disease: An RCT. Neurology, 87, 1274-1280. [Google Scholar] [CrossRef]
|
|
[68]
|
Antushevich, H. (2020) Fecal Microbiota Transplantation in Disease Therapy. Clinica Chimica Acta, 503, 90-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Zhao, Z., et al. (2021) Fecal Microbiota Transplantation Protects Rotenone-Induced Parkinson’s Disease Mice via Suppressing Inflammation Mediated by the Lipopolysaccharide-TLR4 Signaling Pathway through the Microbiota-Gut-Brain Axis. Microbiome, 9, Article No. 226. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Sun, M.F., et al. (2018) Neuroprotective Effects of Fecal Micro-biota Transplantation on MPTP-Induced Parkinson’s Disease Mice: Gut Microbiota, Glial Reaction and TLR4/TNF-α Signaling Pathway. Brain, Behavior, and Immunity, 70, 48-60. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Huang, H., et al. (2019) Fecal Microbiota Transplantation to Treat Parkinson’s Disease with Constipation: A Case Report. Medicine, 98, e16163. [Google Scholar] [CrossRef]
|
|
[72]
|
Kuai, X.Y., et al. (2021) Evaluation of Fecal Microbiota Transplantation in Parkinson’s Disease Patients with Constipation. Microbial Cell Factories, 20, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Xue, L.J., et al. (2020) Fecal Microbiota Transplantation Therapy for Parkinson’s Disease: A Preliminary Study. Medicine, 99, e22035. [Google Scholar] [CrossRef]
|
|
[74]
|
Dailey, F.E., Turse, E.P., Daglilar, E. and Tahan, V. (2019) The Dirty Aspects of Fecal Microbiota Transplantation: A Review of Its Adverse Effects and Complications. Current Opinion in Pharmacology, 49, 29-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Fereshtehnejad, S.M., et al. (2014) Motor, Psychiatric and Fatigue Features Associated with Nutritional Status and Its Effects on Quality of Life in Parkinson’s Disease Patients. PLOS ONE, 9, e91153. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Paul, B.S., et al. (209) Prevalence of Malnutrition in Parkin-son’s Disease and Correlation with Gastrointestinal Symptoms. Annals of Indian Academy of Neurology, 22, 447-452. [Google Scholar] [CrossRef]
|
|
[77]
|
Uyar, G. and Yildiran, H. (2019) A Nutritional Approach to Mi-crobiota in Parkinson’s Disease. Bioscience of Microbiota, Food and Health, 38, 115-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[78]
|
Solch, R.J., et al. (2022) Mediterranean Diet Adherence, Gut Microbio-ta, and Alzheimer’s or Parkinson’s Disease Risk: A Systematic Review. Journal of the Neurological Sciences, 434, Arti-cle ID: 120166. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Barichella, M., et al. (2017) Dietary Habits and Neurological Fea-tures of Parkinson’s Disease Patients: Implications for Practice. Clinical Nutrition, 36, 1054-1061. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Mischley, L.K., Lau, R.C. and Bennett, R.D. (2017) Role of Diet and Nutritional Supplements in Parkinson’s Disease Progression. Oxidative Medicine and Cellular Longevity, 2017, Ar-ticle ID: 6405278. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Włodarek, D. (2019) Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease). Nutrients, 11, Article 169. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Shaafi, S., et al. (2016) The Efficacy of the Ketogenic Diet on Motor Functions in Parkinson’s Disease: A Rat Model. Iranian Journal of Neurology, 15, 63-69.
|
|
[83]
|
Vanitallie, T.B., et al. (2005) Treatment of Parkinson Disease with Diet-Induced Hyperketonemia: A Feasibility Study. Neurology, 64, 728-730. [Google Scholar] [CrossRef]
|
|
[84]
|
Phillips, M.C.L., et al. (2018) Low-Fat versus Keto-genic Diet in Parkinson’s Disease: A Pilot Randomized Controlled trial. Movement Disorders, 33, 1306-1314. [Google Scholar] [CrossRef] [PubMed]
|